Biohaven Shares Jump 25% as FDA Accepts Resubmitted Drug Application

what happened

Biohaven shares rose about 25% to $14.68 on Thursday and were heading for their largest one-day percentage gain since September 2023, according to Dow Jones Market Data, Barron's reported. The company said the FDA had accepted a resubmitted New Drug Application for Vyglxia, its experimental treatment for spinocerebellar ataxia, an inherited neurodegenerative disease.

The gain came while the three major U.S. stock indexes were trading lower. The path to this step has been long: in July 2023 the FDA refused to file the first application, and last November it rejected the second, citing possible bias and weak study design. The agency now plans to convene an advisory committee, with a final decision targeted for the first quarter of 2027.

why it matters

RBC Capital Markets analyst Leonid Timashev said that even assuming a conservative 40% probability of success, the news justifies adding about $6 to the share price. For the broader market this is a single-company story, but it shows how regulatory decisions can quickly reprice small biotech stocks, which had recently fallen after a clinical hold on another drug candidate.

market impact

Biohaven shares: easing of regulatory uncertainty supports the stock, while the risk of rejection remains.

tags

instruments